XBI: A Vehicle For The Transformative Benefits Of Artificial Intelligence Within Biotechnology

Summary

• Artificial Intelligence stands to revolutionize drug discovery and manufacturing in the biotech industry, promising faster, cost-effective processes, which could greatly benefit biotech investors.
• The SPDR S&P Biotech ETF, an equal-weighted fund with broad industry exposure, presents an attractive investment vehicle to leverage these AI-driven changes.
• Despite recent downturns in the biotech sector and XBI's specific exposure to smaller, speculative biotech firms, long-term trends and AI advancements suggest a strong rebound.
• Anticipated improvement in the time and cost of drug discovery due to AI, coupled with easing capital market conditions, will drive small-cap biotech outperformance, an area XBI is heavily exposed.
• Long-Term Equity Anticipation Securities (LEAPS) on XBI tracking the ETF's price movement offer a capital-efficient way for investors to potentially significantly enhance return on invested capital.

Shutter2U

Thesis

Artificial Intelligence enabled drug discovery is poised to disrupt the biotechnology industry to the benefit of shareholders. The SPDR S&P Biotech ETF (NYSEARCA:XBI) offers investors who are looking to gain exposure to the industry a diversified and simple

Analyst’s Disclosure:I/we have a beneficial long position in the shares of XBI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.